Braveheart Bio (NASDAQ:BRVE) Insider Acquires $19,998.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) insider Michele Anderson acquired 1,111 shares of Braveheart Bio stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $19,998.00. Following the completion of the purchase, the insider directly owned 332,161 shares in the company, valued at approximately $5,978,898. This represents a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Braveheart Bio Price Performance

BRVE opened at $30.00 on Monday. Braveheart Bio, Inc. has a 1 year low of $28.47 and a 1 year high of $32.00.

Get Braveheart Bio alerts:

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

Read More

• Five stocks we like better than Braveheart Bio
• Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
• Can DICK’S Turn Foot Locker Into a Winner?
• Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
• Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War

Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.